478TiPA phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease

作者： J. Wolf , M. Hochmair , J.G. Kattan , M.-K. Ang , E.B. Garon

DOI: 10.1093/ANNONC/MDV532.62

关键词: